Novo Nordisk announced a plan to reduce the price of its anti-obesity drug Wegovy by 50% in the U.S. starting in 2027 to improve affordability and competitiveness.
Novo Nordisk, a Danish pharmaceutical company, is making significant moves to regain market position by announcing a 50% price reduction for its popular obesity treatment Wegovy in the United States, effective January 1, 2027. This decision comes in response to increasing competition in the anti-obesity treatment sector and aims to enhance the financial accessibility of the medication for patients and healthcare payers, both public and private. The price adjustment also includes a 35% reduction for another of its drugs, Ozempic, and affects all dosages of these medications.
